Hemostatics in patients with inhibited coagulation-A viscoelastic in-vitro analysis.

Background: The military has used topical hemostatic agents to successfully treat life-threatening external bleeding for years. In contrast to the military environment, the general population are increasingly prescribed anticoagulants. There are only few comparative evaluations of topical hemostatic agents with anticoagulated human blood.

Anticentromere-A and anticentromere-B antibodies show high concordance and similar clinical associations in patients with systemic sclerosis.

Objective: To determine the diagnostic sensitivity and specificity and the clinical usefulness of parallel anticentromere-A and anticentromere-B antibody (anti-CENP-A and anti-CENP-B) testing in patients with systemic sclerosis (SSc).

Methods: Sera from 280 consecutive patients with SSc and 259 controls were tested for the presence of anti-CENP-A and anti-CENP-B antibodies by a monospecific line immunoblot assay (LIA) with recombinant human centromere proteins A and B as well as by indirect immunofluorescence (IIF). Crossreactivity and possible associations with clinical manifestations were studied.

Nutritional status as marker for disease activity and severity predicting mortality in patients with systemic sclerosis.

Objective: To assess and analyse nutritional status in patients with systemic sclerosis (SSc) and identify possible associations with clinical symptoms and its prognostic value.

Methods: Body mass index (BMI) and parameters of bioelectrical impedance analysis (BIA) were assessed in 124 patients with SSc and 295 healthy donors and matched for sex, age and BMI for comparisons. In patients with SSc, BMI and BIA values were compared with clinical symptoms in a cross-sectional study.

Diagnostic value of anti-topoisomerase I antibodies in a large monocentric cohort.

Introduction: In the present study, the detection of anti-topoisomerase I (anti-topo I) autoantibodies was evaluated for diagnosis and risk assessment of systemic sclerosis (SSc) patients in a well characterized large monocentric cohort.

Methods: Sera from patients with SSc (diffuse n = 96, limited n = 113), from patients with overlap syndromes (n = 51), from patients with other diseases associated with SSc (n = 20), as well as from disease controls (n = 487) were analysed for the presence of anti-topo I antibodies by line immunoblot assay and ELISA. Assessment of organ manifestations was performed as proposed by the European Scleroderma Trial and Research network.

Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients.

Introduction: Anti-PM/Scl antibodies are present in sera from patients with polymyositis (PM), systemic sclerosis (SSc), and PM/SSc overlap syndromes. The prevalence of antibodies against the 75- and 100-kDa PM/Scl proteins and their clinical associations have not been studied in SSc patients in detail so far but could provide a valuable tool for risk assessment in these patients. Furthermore, it remains speculative whether commercially available test systems detecting only anti-PM/Scl-100 antibodies are sufficient in SSc patients.